Dietary fat supplement trial for A-T

Ataxia telangiectasia (A-T) is a rare inherited condition that affects the nervous and immune systems. A-T typically impacts movement, vision and speech. The condition can also result in a weakened immune system with frequent infections and an increased risk of cancers such as leukemia and lymphoma. A dietary fat supplement could improve the prognosis and quality of life for Australian children living A-T.

This innovative trial aims to treat mitochondrial dysfunction in A-T using a novel form of anaplerosis.

Children and adults with A-T across Australia are participating in the trial launched by the Federal Health Minister, The Hon. Greg Hunt MP, in 2022.

Redenlab are providing speech, language and mealtime assessments for the children, adolescents and adults in the trial.

For more information, click here.

Related Post

  • Posted on 12 November, 2024
    Redenlab is excited to announce that Prof. Adam Vogel will be speaking at the upcoming International Congress for Ataxia Research...
    • Posted on 14 October, 2024
      Redenlab is pleased to announce that Dr. Adam Vogel, an expert in speech and language function, will be presenting at...
      • Posted on 4 September, 2024
        Dr. Adam Vogel, CSO of Redenlab, will be speaking alongside Dr. Tairmae Kangarloo, Associate Director of Digital Strategy at Takeda,...